Digest Network Come funziona
Network
/
Società
Fo
Non verificato

Forlong Biotechnology

Di cosa scriviamo

BiotecnologiaFarmaceuticaMedicina - VarieOncologiaSalute

10 comunicati stampa

Guarda tutti i comunicati
27/05/2026
Eventi
Industria
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Oncologia
Forlong Announces Completion of Phase I Clinical Studies of FL115 Monotherapy (IV): Disease Control for 3 Heavily-pretreated Patients with Advanced Solid Tumors over 12 Months
Fonte
Forlong Biotechnology
Emittente
Business Wire
1.00
0
19/05/2026
Oncologia
Associazioni/Professionisti
Salute
Finanza
Medicina - Varie
Farmaceutica
Biotecnologia
Industria
Forlong Raises Approximately 120 Million RMB in Series Pre-B Financing to Advance its IL-15 and IL-18 Pipeline
Fonte
Forlong Biotechnology
Emittente
Business Wire
1.00
0
21/04/2026
Fiere
Analisi di mercato
Scienza
Biotecnologia
Farmaceutica
Oncologia
Sanità
Salute
Medicina - Varie
Forlong Biotechnology to Present Clinical Data from the First-in-human Study for FL115 (IL-15 Superagonist) in US Patients with Advanced Solid Tumors at 2026 ASCO Annual Meeting
Fonte
Forlong Biotechnology
Emittente
Business Wire
1.00
0
15/04/2026
Industria
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Forlong Biotechnology Announced CMC Readiness to Initiate GMP Batch Production to Support Upcoming Pivotal Clinical Trial for FL115 (IL-15 Superagonist) in Nonmuscle Invasive Bladder Cancer (NMIBC)
Fonte
Forlong Biotechnology
Emittente
Business Wire
1.00
0
17/03/2026
Eventi
Industria
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Oncologia
Forlong Biotechology to Present Preclinical Data from FL115, a novel interleukin-15 (IL-15) superagonist, and FL116, a PD-1/interleukin-18 (IL-18) bispecific antibody, at the 2026 AACR Annual Meeting
Fonte
Forlong Biotechnology
Emittente
Business Wire
1.00
0
07/01/2026
Eventi
Industria
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Forlong Biotechology Announced Activation of Phase Ib/II Study of FL115 (IL-15 Superagonist) in combination with anti-PD-1 Antibody for Patients with Advanced Solid Tumor and Acceptance of IND for FL115 Subcutaneous Injection by NMPA
Fonte
Forlong Biotechnology
Emittente
Business Wire
1.00
0
30/10/2025
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Eventi
Industria
Forlong Biotechology to Present Clinical Data from FL115, a novel interleukin-15 (IL-15) superagonist, in Late-breaking Session at 40th SITC Annual Meeting
Fonte
Forlong Biotechnology
Emittente
Business Wire
1.00
0
30/10/2025
Eventi
Industria
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Forlong Dosed First Patient in Phase 2 Clinical Trial of FL115, a novel interleukin-15 (IL-15) superagonist, for nonmuscle invasive bladder cancer (NMIBC)
Fonte
Forlong Biotechnology
Emittente
Business Wire
1.00
0
22/10/2025
Oncologia
Salute
Scienza
Farmaceutica
Biotecnologia
Mercato del lavoro
Forlong Biotechology Announces Collaboration Agreement with Henlius to Develop Innovative Cancer Immunotherapy with an Engineered Cytokine
Fonte
Forlong Biotechnology
Emittente
Business Wire
1.00
0
14/10/2025
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Oncologia
Mercato del lavoro
Industria
Forlong Biotechnology Receives Milestone Payment as Partner Submits IND for A Protein Therapy using its Proprietary Fbody® Technology
Fonte
Forlong Biotechnology
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0